Combination glecaprevir, pibrentasvir with ezetimibe prevents HCV in transplantation

LONDON — Combined glecaprevir and pibrentasvir with ezetimibe prevented hepatitis C infection among patients who received non-liver solid organ transplants with HCV viremic grafts, according to research.“We have an availability of safe, well-tolerated and highly effective hepatitis C therapies with direct acting antiviral agents,” Bashar Aqel, MD, a gastroenterologist and transplant hepatologist at the Mayo Clinic in Phoenix, told attendees at the International Liver Congress. “Use of HCV viremic grafts has been associated with a reduced wait time, good graft andRead More

Related Articles